Cue Biopharma (CUE) support and resistance · rev $9.3M
Cue Biopharma (CUE) is a biotechnology company listed on US.
This page maps Cue Biopharma (CUE) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
CUE currently screens at market cap $59.5M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new CUE 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the CUE quote page for the session range and the stock page for the full model.
Not investment advice.